<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323334</url>
  </required_header>
  <id_info>
    <org_study_id>15562</org_study_id>
    <secondary_id>I7X-EW-LLCA</secondary_id>
    <nct_id>NCT02323334</nct_id>
  </id_info>
  <brief_title>A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease</brief_title>
  <official_title>Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves single and multiple doses of LY3202626 and will evaluate the effects of
      LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single
      increasing doses of LY3202626 will be given in capsule form. Part A will also include
      itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B
      will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days
      with the study drug. Part C will last approximately 11-14 weeks. Part D will last
      approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may
      only enroll in one part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (up to 14 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626</measure>
    <time_frame>Day 1 or Day 14, Predose up to 120 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3202626</measure>
    <time_frame>Day 1 or Day 14, Predose up to 120 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration</measure>
    <time_frame>Parts A, C and D: Day 1 or Day 14, Predose up to 120 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Biomarker: Cerebrospinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration</measure>
    <time_frame>Part B: Predose up to 36 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cerebrospinal fluid (CSF) Concentration of LY3202626</measure>
    <time_frame>Parts C and D: Day 15 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Biomarker: Change in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration</measure>
    <time_frame>Parts C and D: Predose up to Day 15 after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>LY3202626 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of LY3202626 given orally in capsule form administered up to once in each of 4 periods in a crossover fashion. Some participants may also receive multiple doses of 200 mg of Itraconazole orally in 1 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part B Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 in capsule form. Dose determined by Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part B Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 in capsule form. Dose determined by Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part B High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 in capsule form. Dose determined by Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part C Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY3202626 in capsule form. Drug is given once daily, for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part C Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part C High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo given in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo given in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of placebo given in capsule form. Placebo is given once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202626</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY3202626 Part A</arm_group_label>
    <arm_group_label>LY3202626 Part B Low dose</arm_group_label>
    <arm_group_label>LY3202626 Part B Mid dose</arm_group_label>
    <arm_group_label>LY3202626 Part B High Dose</arm_group_label>
    <arm_group_label>LY3202626 Part C Low dose</arm_group_label>
    <arm_group_label>LY3202626 Part C Mid dose</arm_group_label>
    <arm_group_label>LY3202626 Part C High dose</arm_group_label>
    <arm_group_label>LY3202626 Part D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part A, B, C)</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Placebo Part A</arm_group_label>
    <arm_group_label>Placebo Part B</arm_group_label>
    <arm_group_label>Placebo Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>administered orally</description>
    <arm_group_label>LY3202626 Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Parts A, B, and C, are overtly healthy males or females (nonchildbearing
             potential), as determined by medical history and physical examination

          -  Have a body mass index (BMI) of 18 to 32 kilograms per square meter (kg/m^2)

          -  For Part D, present with Mild Cognitive Impairment (MCI) due to Alzheimer's Disease
             (AD) or mild to moderate AD

          -  Have venous access sufficient to allow for blood sampling

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures and research unit policies

        Exclusion Criteria:

          -  Taking over-the-counter or prescription medication with the exception of vitamins or
             minerals

          -  Smoke more than 10 cigarettes per day

          -  Are unwilling or unable to refrain from eating any food or drinking any beverage
             containing grapefruit or grapefruit juice for at least 2 weeks prior to first dose
             until completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

